外科領域におけるCefotaximeの基礎的・臨床的検討 (Cefotaxime<特集>)

概要

論文の詳細を見る
We shall report on the several findings obtained from our basic studies and clinical trials of cefotaxime (HR 756, CTX), a newly developed cephalosporin antibiotic. 1. MICs of cefotaxime were determined against clinical isolates. E. coli and Klebsiella were highly susceptible to cefotaxime with the peak distributions at 0.2 μ g/ml. P. aeruginosa was also susceptible to cefotaxime, 88% of the strains being inhibited by 50 μ g/ml or below. 2. Cefotaxime was intravenously injected to 2 patients with external biliary fistulas and the concentrations of the drug in the bile were determined. Peak levels of 5.1 and 6.1 μ g/ml were attained after 2 hours. 3. Cefotaxime was used in 11 cases of surgical infections. The drug efficacy was evaluated as follows; Excellent: 1 Good: 5 Fair: 5 These are relatively favorable results. 4. As for adverse reactions, no abnormalities attributable to cefotaxime were detected.
公益社団法人日本化学療法学会の論文